Avalo Therapeutics Inc. (C6K0)
XDUS 
Summary
C6K0 Chart
Wall Street Analysts Predict an 113.34% Upside in Avalo Therapeutics (AVTX): Here's What You Should Know
The average of price targets set by Wall Street analysts indicates a potential upside of 113.3% in Avalo Therapeutics (AVTX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
5 Small Drug Stocks to Buy as Sector Recovery Gains Strength
Innovation is at its peak in the Zacks Medical-Drugs industry. INDV, CPRX, TBPH, RLMD and AVTX may prove to be good additions to one's portfolio.
Ally Bridge Group NY LLC Purchases New Position in Avalo Therapeutics, Inc. $AVTX
Ally Bridge Group NY LLC acquired a new position in Avalo Therapeutics, Inc. (NASDAQ: AVTX) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 178,100 shares of the company's stock, valued at approximately $2,264,000. Avalo Therapeutics comprises 1.4% of Ally Bridge Group
Avalo Therapeutics Inc. (C6K0) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Avalo Therapeutics Inc. ever had a stock split?
Avalo Therapeutics Inc. Profile
| Biotechnology Industry | Healthcare Sector | Garry A. Neil CEO | XDUS Exchange | US05338F3064 ISIN |
| US Country | 33 Employees | - Last Dividend | 29 Dec 2023 Last Split | - IPO Date |
Overview
Avalo Therapeutics, Inc. presents itself as a cutting-edge biotechnology entity heavily involved in the clinical phase, specifically targeting the discovery and creation of innovative therapies aimed at rectifying immune dysregulation within the United States. The inception of the company traces back to 2011, with its headquarters nestled in Rockville, Maryland. Avalo embarked on its journey under the name Cerecor Inc., later rebranding to Avalo Therapeutics, Inc. in August 2021. This strategic move marked a pivotal phase in the company’s ambition to carve out a niche in the realm of immune dysregulation therapies.
Products and Services
AVTX-009: Anti-IL-1ß monoclonal antibody - Positioned in Phase I of clinical trials, AVTX-009 represents Avalo Therapeutics' venture into pioneering treatments for inflammatory diseases. This developmental candidate embodies the company's endeavor to bring forth a solution that targets the root causes of immune dysregulation through meticulous scientific and medical advancements.
AVTX-008: Fully human B and T lymphocyte attenuator - A cutting-edge fusion protein designed as an agonist, AVTX-008 is meticulously engineered for the treatment of immune dysregulation disorders. This innovative approach signifies Avalo's commitment to addressing complex immune responses, paving the way for potential breakthroughs in treatment paradigms.
Quisovalimab (AVTX-002): Anti-LIGHT mAb - Currently advancing through phase II trials, Quisovalimab marks Avalo Therapeutics' strategic expansion into addressing immune-inflammatory diseases. This Anti-LIGHT monoclonal antibody demonstrates the company’s dedication to exploring new frontiers in therapeutic development, aiming to alleviate sufferings caused by immune-related disorders.
